JP2022531288A - 適応治療管理システム - Google Patents
適応治療管理システム Download PDFInfo
- Publication number
- JP2022531288A JP2022531288A JP2021564700A JP2021564700A JP2022531288A JP 2022531288 A JP2022531288 A JP 2022531288A JP 2021564700 A JP2021564700 A JP 2021564700A JP 2021564700 A JP2021564700 A JP 2021564700A JP 2022531288 A JP2022531288 A JP 2022531288A
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- patient
- data
- score
- treatment regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 419
- 230000003044 adaptive effect Effects 0.000 title abstract description 6
- 238000011269 treatment regimen Methods 0.000 claims abstract description 210
- 238000005457 optimization Methods 0.000 claims abstract description 80
- 238000007726 management method Methods 0.000 claims abstract description 62
- 239000003814 drug Substances 0.000 claims description 115
- 229940079593 drug Drugs 0.000 claims description 113
- 238000000034 method Methods 0.000 claims description 71
- 206010019280 Heart failures Diseases 0.000 claims description 60
- 230000006854 communication Effects 0.000 claims description 43
- 208000024891 symptom Diseases 0.000 claims description 41
- 238000004891 communication Methods 0.000 claims description 40
- 230000004044 response Effects 0.000 claims description 23
- 230000036541 health Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 230000036772 blood pressure Effects 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- 239000012530 fluid Substances 0.000 description 12
- 239000002934 diuretic Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 206010003658 Atrial Fibrillation Diseases 0.000 description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- 239000005541 ACE inhibitor Substances 0.000 description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 6
- 230000006793 arrhythmia Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- 238000009125 cardiac resynchronization therapy Methods 0.000 description 5
- 229940030606 diuretics Drugs 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000000422 nocturnal effect Effects 0.000 description 5
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 229940097320 beta blocking agent Drugs 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 230000001882 diuretic effect Effects 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- 238000011285 therapeutic regimen Methods 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 2
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 206010003668 atrial tachycardia Diseases 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 238000010587 phase diagram Methods 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 230000005195 poor health Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102400001263 NT-proBNP Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010031123 Orthopnoea Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940100321 entresto Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- ZASXKEGREHRXDL-CAWNUZPDSA-H hexasodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1 ZASXKEGREHRXDL-CAWNUZPDSA-H 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037909 invasive meningococcal disease Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 208000012144 orthopnea Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 229940100334 sacubitril / valsartan Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3629—Heart stimulators in combination with non-electric therapy
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/112—Gait analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B7/00—Instruments for auscultation
- A61B7/02—Stethoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36585—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by two or more physical parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/37—Monitoring; Protecting
- A61N1/3706—Pacemaker parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37211—Means for communicating with stimulators
- A61N1/37252—Details of algorithms or data aspects of communication system, e.g. handshaking, transmitting specific data or segmenting data
- A61N1/37282—Details of algorithms or data aspects of communication system, e.g. handshaking, transmitting specific data or segmenting data characterised by communication with experts in remote locations using a network
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Physiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Urology & Nephrology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Acoustics & Sound (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962844697P | 2019-05-07 | 2019-05-07 | |
| US62/844,697 | 2019-05-07 | ||
| PCT/US2020/030722 WO2020227009A1 (en) | 2019-05-07 | 2020-04-30 | Adaptive treatment management system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022531288A true JP2022531288A (ja) | 2022-07-06 |
Family
ID=70779908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564700A Pending JP2022531288A (ja) | 2019-05-07 | 2020-04-30 | 適応治療管理システム |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200353250A1 (de) |
| EP (1) | EP3966828A1 (de) |
| JP (1) | JP2022531288A (de) |
| CN (1) | CN113795890A (de) |
| WO (1) | WO2020227009A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220301709A1 (en) * | 2017-12-20 | 2022-09-22 | Medi Whale Inc. | Diagnosis assistance method and cardiovascular disease diagnosis assistance method |
| US12057206B2 (en) * | 2019-05-31 | 2024-08-06 | International Business Machines Corporation | Personalized medication non-adherence evaluation |
| US11642078B2 (en) | 2019-12-05 | 2023-05-09 | Medtronic, Inc. | Intervention for heart failure management |
| US20220101971A1 (en) * | 2020-09-28 | 2022-03-31 | Optum, Inc. | Predictive data analysis techniques for generating optimized drug delivery arrangements |
| TWI845433B (zh) * | 2022-11-17 | 2024-06-11 | 美商道思倍司股份有限公司 | 人體壓力感測系統 |
| WO2024125969A1 (en) * | 2022-12-14 | 2024-06-20 | Biotronik Se & Co. Kg | Method and system for a medication plan dependent alert generation by an implantable medical device |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579280B1 (en) | 1999-04-30 | 2003-06-17 | Medtronic, Inc. | Generic multi-step therapeutic treatment protocol |
| US6635048B1 (en) | 1999-04-30 | 2003-10-21 | Medtronic, Inc. | Implantable medical pump with multi-layer back-up memory |
| US7054782B2 (en) | 2000-12-29 | 2006-05-30 | Medtronic, Inc. | Non-conformance monitoring and control techniques for an implantable medical device |
| US7001359B2 (en) | 2001-03-16 | 2006-02-21 | Medtronic, Inc. | Implantable therapeutic substance infusion device with active longevity projection |
| US7264611B2 (en) | 2002-05-31 | 2007-09-04 | Medtronic, Inc. | Implantable infusion device with motor connection and seal system |
| US20040087864A1 (en) * | 2002-10-30 | 2004-05-06 | Lawrence Grouse | Method and apparatus for assessment and treatment of cardiac risk |
| US7986994B2 (en) | 2002-12-04 | 2011-07-26 | Medtronic, Inc. | Method and apparatus for detecting change in intrathoracic electrical impedance |
| US7433853B2 (en) * | 2004-07-12 | 2008-10-07 | Cardiac Pacemakers, Inc. | Expert system for patient medical information analysis |
| US8271080B2 (en) * | 2007-05-23 | 2012-09-18 | Cardiac Pacemakers, Inc. | Decongestive therapy titration for heart failure patients using implantable sensor |
| US8676303B2 (en) * | 2008-05-13 | 2014-03-18 | The Regents Of The University Of California | Methods and systems for treating heart instability |
| US9713701B2 (en) | 2008-07-31 | 2017-07-25 | Medtronic, Inc. | Using multiple diagnostic parameters for predicting heart failure events |
| WO2011126823A1 (en) * | 2010-03-29 | 2011-10-13 | Medtronic, Inc. | Method and apparatus for monitoring tissue fluid content for use in an implantable cardiac device |
| JP2012038818A (ja) | 2010-08-04 | 2012-02-23 | Toshiba Corp | 半導体装置 |
| US20120203573A1 (en) * | 2010-09-22 | 2012-08-09 | I.D. Therapeutics Llc | Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns |
| US10286146B2 (en) * | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| JP6190033B2 (ja) * | 2013-03-14 | 2017-08-30 | カーディアック ペースメイカーズ， インコーポレイテッド | 再入院を回避するための心不全管理 |
| US9345550B2 (en) * | 2013-10-31 | 2016-05-24 | Pacesetter, Inc. | Method and system for characterizing stimulus sites and providing implant guidance |
| US10617349B2 (en) * | 2013-11-27 | 2020-04-14 | Medtronic, Inc. | Precision dialysis monitoring and synchronization system |
| US10430557B2 (en) * | 2014-11-17 | 2019-10-01 | Elwha Llc | Monitoring treatment compliance using patient activity patterns |
| US9675270B2 (en) | 2015-04-23 | 2017-06-13 | Medtronic, Inc. | Method and apparatus for determining a premature ventricular contraction in a medical monitoring device |
| WO2016205666A1 (en) * | 2015-06-18 | 2016-12-22 | Medsentry, Inc. | Medication dispensing device and method |
| CN108135534B (zh) * | 2015-08-26 | 2022-04-05 | 瑞思迈传感器技术有限公司 | 监测和管理慢性疾病的系统与方法 |
| CA3007104A1 (en) * | 2015-12-02 | 2017-06-08 | Icahn School Of Medicine At Mount Sinai | Systems and methods for optimizing management of patients with medical devices and monitoring compliance |
| US20170245794A1 (en) * | 2016-02-29 | 2017-08-31 | Medtronic, Inc. | Medical system for seamless therapy adjustment |
| US11139081B2 (en) * | 2016-05-02 | 2021-10-05 | Bao Tran | Blockchain gene system |
| EP4385398A3 (de) * | 2016-11-16 | 2024-07-31 | ONWARD Medical N.V. | Aktives medizinisches system mit geschlossenem regelkreis |
| US20180272066A1 (en) * | 2017-03-24 | 2018-09-27 | Medtronic Minimed, Inc. | Patient management systems and adherence recommendation methods |
| US10952681B2 (en) | 2017-09-05 | 2021-03-23 | Medtronic, Inc. | Differentiation of heart failure risk scores for heart failure monitoring |
| US10702213B2 (en) | 2017-09-05 | 2020-07-07 | Medtronics, Inc. | Differentiation of heart failure risk scores for heart failure monitoring |
| WO2019210095A1 (en) | 2018-04-26 | 2019-10-31 | Medtronic, Inc. | Medical system for therapy adjustment |
| US20220130508A1 (en) * | 2019-02-11 | 2022-04-28 | Fresenius Medical Care Holdings, Inc. | Sharing Dialysis Machines |
| WO2020206062A1 (en) * | 2019-04-02 | 2020-10-08 | Shifamed Holdings, Llc | Systems and methods for monitoring health conditions |
-
2020
- 2020-04-30 US US16/863,340 patent/US20200353250A1/en active Pending
- 2020-04-30 JP JP2021564700A patent/JP2022531288A/ja active Pending
- 2020-04-30 CN CN202080033747.0A patent/CN113795890A/zh active Pending
- 2020-04-30 WO PCT/US2020/030722 patent/WO2020227009A1/en unknown
- 2020-04-30 EP EP20727477.0A patent/EP3966828A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3966828A1 (de) | 2022-03-16 |
| US20200353250A1 (en) | 2020-11-12 |
| WO2020227009A1 (en) | 2020-11-12 |
| CN113795890A (zh) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531288A (ja) | 適応治療管理システム | |
| US20210093254A1 (en) | Determining likelihood of an adverse health event based on various physiological diagnostic states | |
| CA3146965A1 (en) | Blood glucose control system | |
| US12005258B2 (en) | Medical system for therapy adjustment | |
| EP3422928B1 (de) | Medizinisches system zur nahtlosen therapieanpassung | |
| US20120046528A1 (en) | System and method for detecting and treating cardiovascular disease | |
| US20140275827A1 (en) | Method and system for deriving effectiveness of medical treatment of a patient | |
| WO2013154783A1 (en) | Feedback-based diuretic or natriuretic molecule administration | |
| CN107921266B (zh) | 用于对患者进行心力衰竭事件风险分层的基于绝对胸内阻抗的方案 | |
| EP3796831B1 (de) | Messung zum management von herzinsuffizienz | |
| US12109007B2 (en) | Sensing for heart failure management | |
| CN116472585A (zh) | 症状记录器 | |
| US11065442B2 (en) | Implantable medical device which may be controlled from central station | |
| EP4059425B1 (de) | Detektion und/oder vorhersage eines medizinischen zustands unter verwendung von vorhofflimmer- und glukosemessungen | |
| WO2023203411A1 (en) | Closed loop care system based on compliance with a prescribed medication plan | |
| WO2023203450A1 (en) | Sensing and diagnosing adverse health event risk | |
| WO2023203412A1 (en) | Closed loop adjustment of heart failure therapy | |
| WO2023203437A1 (en) | High-resolution diagnostic data system for patient recovery after heart failure intervention | |
| WO2021113592A1 (en) | Intervention for heart failure management | |
| WO2023203414A1 (en) | Exercise tolerance using an implantable or wearable heart monitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230427 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240822 |